![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
T Shimada, H Yamazaki, M Mimura, Y Inui and FP Guengerich
Osaka Prefectural Institute of Public Health, Japan.
Interindividual variations in the level and activity of cytochrome P- 450 enzymes were investigated in the liver microsomes of 30 Japanese and 30 Caucasian patients. The P-450 enzymes used in this study included P-450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A, and the monooxygenase activities determined were 13 typical P-450 substrates and 9 procarcinogens. Although the total P-450 content was higher in Caucasian (mean, 0.43 nmol/mg of protein) than in Japanese populations (mean, 0.26 nmol/mg of protein), the relative levels (percent of total P-450) of individual forms of P-450 determined immunochemically were not very different except that P-450 2A6 and 2B6 levels were higher in the Caucasians. About 70% of liver P-450 could be accounted for by P- 450 1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A proteins, and P-450 3A (about 30% of total P-450) and 2C (about 20%) enzymes were found to be the major forms. Considerable levels of P-450 1A2 (about 13%) and 2E1 (about 7%) could be determined, whereas the P-450 2A6 (about 4%), 2D6 (about 2%) and 2B6 (< 1%) were the minor P-450 forms. Differences in some of the P-450 1A2-, 2A6-, 2D6-, 2E1- and 3A4-dependent activities were observed in Japanese and Caucasian populations. No clear sex- related differences in individual P-450 contents and drug- and carcinogen-metabolizing activities were detected in 60 human samples, except that P-450 1A2-dependent activities were found to be higher in mean than in women in the Caucasian population only. A single neonate sample tended to be lower in P-450 1A2-, 2A6- and 2E1-dependent activities. In contrast to rat counterparts, we could not detect apparent developmental changes in P-450 content and activity in humans between 12 and 73 years old. Thus, the results presented in this study provide useful information for the study of drug biotransformation in humans and for the basis of drug toxicities, carcinogenesis and teratogenesis.
This article has been cited by other articles:
|
|
 |
|
  M. R. Franklin and L. B. Hathaway 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) Revisited: Comparative Cytochrome P450 Inhibition in Human Liver Microsomes by SKF525A, Its Metabolites, and SKF-Acid and SKF-Alcohol Drug Metab. Dispos., December 1, 2008; 36(12): 2539 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Porubsky, K. M. Meneely, and E. E. Scott Structures of Human Cytochrome P-450 2E1: INSIGHTS INTO THE BINDING OF INHIBITORS AND BOTH SMALL MOLECULAR WEIGHT AND FATTY ACID SUBSTRATES J. Biol. Chem., November 28, 2008; 283(48): 33698 - 33707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kupfer, L. Swanson, S. Chow, R. E. Staub, Y. L. Zhang, I. Cohen, and U. Christians Oxidative in Vitro Metabolism of Liquiritigenin, a Bioactive Compound Isolated from the Chinese Herbal Selective Estrogen {beta}-Receptor Agonist MF101 Drug Metab. Dispos., November 1, 2008; 36(11): 2261 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miyazaki, K. Nakamura, Y. Fujita, F. P. Guengerich, R. Horiuchi, and K. Yamamoto Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone Drug Metab. Dispos., November 1, 2008; 36(11): 2287 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Greenblatt and L. L. von Moltke Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs J. Clin. Pharmacol., November 1, 2008; 48(11): 1350 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Murphy The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008 Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsubara, K. Yoshinari, K. Aoyama, M. Sugawara, Y. Sekiya, K. Nagata, and Y. Yamazoe Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo Drug Metab. Dispos., October 1, 2008; 36(10): 2058 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, L. J. Christopher, D. Cui, W. Li, R. Iyer, W. G. Humphreys, and D. Zhang Identification of the Human Enzymes Involved in the Oxidative Metabolism of Dasatinib: An Effective Approach for Determining Metabolite Formation Kinetics Drug Metab. Dispos., September 1, 2008; 36(9): 1828 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Ehnert, A. K. Nussler, A. Lehmann, and S. Dooley Blood Monocyte-Derived Neohepatocytes as in Vitro Test System for Drug Metabolism Drug Metab. Dispos., September 1, 2008; 36(9): 1922 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Stevens, S. A. Marsh, M. J. Zaya, K. J. Regina, K. Divakaran, M. Le, and R. N. Hines Developmental Changes in Human Liver CYP2D6 Expression Drug Metab. Dispos., August 1, 2008; 36(8): 1587 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hilli, T. Korhonen, M. Turpeinen, J. Hokkanen, S. Mattila, and K. Laine The Effect of Oral Contraceptives on the Pharmacokinetics of Melatonin in Healthy Subjects With CYP1A2 g.-163C>A Polymorphism J. Clin. Pharmacol., August 1, 2008; 48(8): 986 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamada, N. Metoki, H. Yoshida, K. Satoh, K. Kato, T. Hibino, K. Yokoi, S. Watanabe, S. Ichihara, Y. Aoyagi, et al. Genetic Factors for Ischemic and Hemorrhagic Stroke in Japanese Individuals Stroke, August 1, 2008; 39(8): 2211 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kumar, R. C. Brundage, W. S. Oetting, I. E. Leppik, and T. S. Tracy Differential Genotype Dependent Inhibition of CYP2C9 in Humans Drug Metab. Dispos., July 1, 2008; 36(7): 1242 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Kramer, A. E. Rettie, M. J. Rieder, E. T. Cabacungan, and R. N. Hines Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression Mol. Pharmacol., June 1, 2008; 73(6): 1751 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Sinues, A Fanlo, E Mayayo, C Carcas, J Vicente, I Arenaz, and A Cebollada CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives Human and Experimental Toxicology, May 1, 2008; 27(5): 367 - 372. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Wang, X. Ma, K. W. Krausz, J. R. Idle, and F. J. Gonzalez Role of Pregnane X Receptor in Control of All-Trans Retinoic Acid (ATRA) Metabolism and Its Potential Contribution to ATRA Resistance J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 674 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chen, R.-A. Cue, K. Lundstrom, J. D. Wood, and O. Doran Regulation of CYP2A6 Protein Expression by Skatole, Indole, and Testicular Steroids in Primary Cultured Pig Hepatocytes Drug Metab. Dispos., January 1, 2008; 36(1): 56 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. K. Walle and T. Walle Bioavailable Flavonoids: Cytochrome P450-Mediated Metabolism of Methoxyflavones Drug Metab. Dispos., November 1, 2007; 35(11): 1985 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vuppugalla, S.-Y. Chang, H. Zhang, P. H. Marathe, and D. A. Rodrigues Effect of Commonly Used Organic Solvents on the Kinetics of Cytochrome P450 2B6- and 2C8-Dependent Activity in Human Liver Microsomes Drug Metab. Dispos., November 1, 2007; 35(11): 1990 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, S. S. Lee, H.-E. Jeong, J.-H. Shon, J.-Y. Ryu, Y. E. Sunwoo, K.-H. Liu, W. Kang, Y.-J. Park, C.-M. Shin, et al. The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals Drug Metab. Dispos., November 1, 2007; 35(11): 2095 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Perrett, Z. E. Barter, B. C. Jones, H. Yamazaki, G. T. Tucker, and A. Rostami-Hodjegan Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes Drug Metab. Dispos., October 1, 2007; 35(10): 1733 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Yoon, K.-B. Kim, H. Kim, K.-A. Seo, H.-S. Kim, I.-J. Cha, E.-Y. Kim, K.-H. Liu, and J.-G. Shin Characterization of Benidipine and Its Enantiomers' Metabolism by Human Liver Cytochrome P450 Enzymes Drug Metab. Dispos., September 1, 2007; 35(9): 1518 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ballard, T. Prueksaritanont, and C. Tang Hepatic Metabolism of MK-0457, a Potent Aurora Kinase Inhibitor: Interspecies Comparison and Role of Human Cytochrome P450 and Flavin-Containing Monooxygenase Drug Metab. Dispos., September 1, 2007; 35(9): 1447 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Aitken and E. T. Morgan Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes Drug Metab. Dispos., September 1, 2007; 35(9): 1687 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Gorman, L. Coward, C. Kerstner-Wood, L. Cork, I. M. Kapetanovic, W. J. Brouillette, and D. D. Muccio In Vitro Metabolic Characterization, Phenotyping, and Kinetic Studies of 9cUAB30, a Retinoid X Receptor-Specific Retinoid Drug Metab. Dispos., July 1, 2007; 35(7): 1157 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tegude, A. Schnabel, U. M. Zanger, K. Klein, M. Eichelbaum, and O. Burk Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4{alpha}: Evidence for Direct Regulation in the Intestine Drug Metab. Dispos., June 1, 2007; 35(6): 946 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, D. Zhang, W. Li, M. Yao, C. D'Arienzo, Y.-X. Li, W. R. Ewing, Z. Gu, Y. Zhu, N. Murugesan, et al. Reduction of Site-Specific CYP3A-Mediated Metabolism for Dual Angiotensin and Endothelin Receptor Antagonists in Various in Vitro Systems and in Cynomolgus Monkeys Drug Metab. Dispos., May 1, 2007; 35(5): 795 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Higashi, M. Nakajima, M. Katoh, S. Tokudome, and T. Yokoi Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6 Drug Metab. Dispos., April 1, 2007; 35(4): 508 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Isin and F. P. Guengerich Multiple Sequential Steps Involved in the Binding of Inhibitors to Cytochrome P450 3A4 J. Biol. Chem., March 2, 2007; 282(9): 6863 - 6874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ogasawara, T. Kume, and E. Kazama Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys Drug Metab. Dispos., March 1, 2007; 35(3): 410 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. O'Donnell, K. Grime, P. Courtney, D. Slee, and R. J. Riley The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting Drug Metab. Dispos., March 1, 2007; 35(3): 381 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Torimoto, I. Ishii, K.-I. Toyama, M. Hata, K. Tanaka, H. Shimomura, H. Nakamura, N. Ariyoshi, S. Ohmori, and M. Kitada Helices F-G Are Important for the Substrate Specificities of CYP3A7 Drug Metab. Dispos., March 1, 2007; 35(3): 484 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Endo, M. Ban, K. Hirata, A. Yamamoto, Y. Hara, and Y. Momose Involvement of CYP2A6 in the Formation of a Novel Metabolite, 3-Hydroxypilocarpine, from Pilocarpine in Human Liver Microsomes Drug Metab. Dispos., March 1, 2007; 35(3): 476 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Medina-Diaz, G. Arteaga-Illan, M. B. de Leon, B. Cisneros, A. Sierra-Santoyo, L. Vega, F. J. Gonzalez, and G. Elizondo Pregnane X Receptor-Dependent Induction of the CYP3A4 Gene by o,p'-1,1,1,-Trichloro-2,2-Bis (p-Chlorophenyl)ethane Drug Metab. Dispos., January 1, 2007; 35(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, I. P. van der Heiden, J. A. Goldstein, and R. H. N. van Schaik A New CYP3A5 Variant, CYP3A5*11, Is Shown to Be Defective in Nifedipine Metabolism in a Recombinant cDNA Expression System Drug Metab. Dispos., January 1, 2007; 35(1): 67 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Krishnan and S. Moncrief An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes Drug Metab. Dispos., January 1, 2007; 35(1): 180 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Davies, J. K. Coller, A. A. Somogyi, R. W. Milne, and B. C. Sallustio CYP2B6, CYP2D6, and CYP3A4 Catalyze the Primary Oxidative Metabolism of Perhexiline Enantiomers by Human Liver Microsomes Drug Metab. Dispos., January 1, 2007; 35(1): 128 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Koukouritaki, M. T. Poch, M. C. Henderson, L. K. Siddens, S. K. Krueger, J. E. VanDyke, D. E. Williams, N. M. Pajewski, T. Wang, and R. N. Hines Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 266 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T.M. Buters Effective Strategies for Tumors Affecting Chemopreventive Metabolism Clin. Cancer Res., December 15, 2006; 12(24): 7203 - 7204. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky, A. V. Astuccio, and R. S. Obach Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6. J. Clin. Pharmacol., December 1, 2006; 46(12): 1426 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Itoh, M. Nakajima, E. Higashi, R. Yoshida, K. Nagata, Y. Yamazoe, and T. Yokoi Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator 1{alpha} J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 693 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamazaki, M. Shimizu, T. Nagashima, M. Minoshima, and N. Murayama Rat Cytochrome P450 2C11 in Liver Microsomes Involved in Oxidation of Anesthetic Agent Propofol and Deactivated by Prior Treatment with Propofol Drug Metab. Dispos., November 1, 2006; 34(11): 1803 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Carr, R. Norcross, Y. Fang, P. Lu, A. D. Rodrigues, M. Shou, T. Rushmore, and C. Booth-Genthe Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes Drug Metab. Dispos., October 1, 2006; 34(10): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, X.-X. Yang, M. Huang, Z.-P. Hu, M. He, W. Duan, E. Chan, F.-S. Sheu, X. Chen, and S.-F. Zhou Small Interfering RNA-Mediated Silencing of Cytochrome P450 3A4 Gene Drug Metab. Dispos., September 1, 2006; 34(9): 1650 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Usmani, T. M. Cho, R. L. Rose, and E. Hodgson Inhibition of the Human Liver Microsomal and Human Cytochrome P450 1A2 and 3A4 Metabolism of Estradiol by Deployment-Related and Other Chemicals Drug Metab. Dispos., September 1, 2006; 34(9): 1606 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-K. Lee, J.-K. Moon, C.-H. Chang, H. Choi, H.-W. Park, B.-S. Park, H.-S. Lee, E.-C. Hwang, Y.-D. Lee, K.-H. Liu, et al. STEREOSELECTIVE METABOLISM OF ENDOSULFAN BY HUMAN LIVER MICROSOMES AND HUMAN CYTOCHROME P450 ISOFORMS Drug Metab. Dispos., July 1, 2006; 34(7): 1090 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wang, A. J. Mendy, G. Dai, H.-R. Luo, L. He, and Y.-J. Y. Wan Retinoids Activate the RXR/SXR-Mediated Pathway and Induce the Endogenous CYP3A4 Activity in Huh7 Human Hepatoma Cells Toxicol. Sci., July 1, 2006; 92(1): 51 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimizu, K. Akimoto, T. Yoshimura, T. Niwa, K. Kobayashi, M. Tsunoo, and K. Chiba AUTOINDUCTION OF MKC-963 [(R)-1-(1-CYCLOHEXYLETHYLAMINO)-4-PHENYLPHTHALAZINE] METABOLISM IN HEALTHY VOLUNTEERS AND ITS RETROSPECTIVE EVALUATION USING PRIMARY HUMAN HEPATOCYTES AND CDNA-EXPRESSED ENZYMES Drug Metab. Dispos., June 1, 2006; 34(6): 950 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kawashima, K. Kobayashi, K. Takama, T. Higuchi, T. Furihata, M. Hosokawa, and K. Chiba INVOLVEMENT OF HEPATOCYTE NUCLEAR FACTOR 4{alpha} IN THE DIFFERENT EXPRESSION LEVEL BETWEEN CYP2C9 AND CYP2C19 IN THE HUMAN LIVER Drug Metab. Dispos., June 1, 2006; 34(6): 1012 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, J.-W. Zhang, W. Li, H. Ma, J. Sun, M.-C. Deng, and L. Yang Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes Toxicol. Sci., June 1, 2006; 91(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Paine, H. L. Hart, S. S. Ludington, R. L. Haining, A. E. Rettie, and D. C. Zeldin THE HUMAN INTESTINAL CYTOCHROME P450 "PIE" Drug Metab. Dispos., May 1, 2006; 34(5): 880 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. Ueng, M.-J. Don, W.-C. Jan, S.-Y. Wang, L.-K. Ho, and C.-F. Chen OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450 Drug Metab. Dispos., May 1, 2006; 34(5): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Goda, D. Nagai, Y. Akiyama, K. Nishikawa, I. Ikemoto, Y. Aizawa, K. Nagata, and Y. Yamazoe DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS Drug Metab. Dispos., May 1, 2006; 34(5): 828 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mitsuda, M. Iwasaki, and S. Asahi Cynomolgus Monkey Cytochrome P450 2C43: cDNA Cloning, Heterologous Expression, Purification and Characterization. J. Biochem., May 1, 2006; 139(5): 865 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Isin and F. P. Guengerich Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4 J. Biol. Chem., April 7, 2006; 281(14): 9127 - 9136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. F. Rehmel, J. A. Eckstein, N. A. Farid, J. B. Heim, S. C. Kasper, A. Kurihara, S. A. Wrighton, and B. J. Ring INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Drug Metab. Dispos., April 1, 2006; 34(4): 600 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Pikuleva CHOLESTEROL-METABOLIZING CYTOCHROMES P450 Drug Metab. Dispos., April 1, 2006; 34(4): 513 - 520. [Abstract] [Full Text] [PDF]
|
